Samsung Electronics Co.'s research and development (R&D) spending for the first nine months of the year hit a record high of 15.89 trillion won, representing a 600 billion-won increase from a year earlier.
It was also over 5 trillion won from its R&D investment tally in the first half of the year.
Samsung's investment in research has been consistently increasing since 2017 when it spent 16.8 trillion won, to 2018 when it allocated 18.7 trillion won, and in 2019 when it spent 20.2 trillion won.
In the third quarter, the South Korean tech giant registered 4,974 patents locally and 6,321 patents in the US.
It has registered 194,643 patents globally, with 77,016 patents of those in the US.
Samsung's capital expenditure is expected to reach 35.2 trillion won this year, the first time since 2017 to surpass the 30-trillion won mark.
In the first nine months, its capital expenditure reached 25.5 trillion won, up 52 percent from the same period last year.


Meta Raises 2026 Capex Outlook Amid AI Spending Surge, Shares Drop After Earnings
Ford Q1 Earnings Beat Expectations, Stock Surges on Strong Guidance
Google Secures Pentagon AI Deal for Classified Projects
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth
Australia Targets Meta, Google, and TikTok With New News Payment Tax Proposal
Samsung Reports Record Profit as AI Boom Drives Memory Chip Demand
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings
Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth
Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S.
Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand
Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales
T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth 



